FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
VIS-101 targets VEGF-A and ANG-2 with a bispecific tetravalent format designed to increase ligand affinity and binding capacity, aiming to improve anatomic/visual outcomes and extend dosing intervals.
GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-t ...
The FDA assigned a PDUFA target action date of December 22, 2026 - - The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction ...
Amylyx (AMLX) downgraded to Buy after AMX0035 PSP halt; focus shifts to avexitide Phase 3 with Q3 2026 data and strong cash ...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...
All in all, the Wyoming Valley Conference fared quite well in the first round of the PIAA state basketball playoffs.
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Why settle for a static Linux Mint desktop when you can jazz it up with this Conky daily quote generator desklet?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results